Current status and future potential of ex vivo lung perfusion in clinical lung transplantation
Artificial Organs · 2023-11 · 47 (11) · 1700-1709
DOI: 10.1111/aor.14607 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Artificial Organs, online erschienen am 16.07.2023. Verfasst von Alice L Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Lung, Lung Transplantation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Lung transplantation is accepted as a well‐established and effective treatment for patients with end‐stage lung disease. While the number of candidates added to the waitlist continues to rise, the number of transplants performed remains limited by the number of suitable organ donors. Ex vivo lung perfusion (EVLP) emerged as a method of addressing the organ shortage by allowing the evaluation and potential reconditioning of marginal donor lungs or minimizing risks of prolonged ischemic time due to logistical challenges. The currently available FDA‐approved EVLP systems have demonstrated excellent outcomes in clinical trials, and retrospective studies have demonstrated similar post‐transplant survival between recipients who received marginal donor lungs perfused using EVLP and recipients who received standard criteria lungs stored using conventional methods. Despite this, widespread utilization has plateaued in the last few years, likely due to the significant costs associated with initiating EVLP programs. Centralized, dedicated EVLP perfusion centers are currently being investigated as a potential method of further expanding utilization of this technology. In the preclinical setting, potential applications of EVLP that are currently being studied include prolongation of organ preservation, reconditioning of unsuitable lungs, and further enhancement of already suitable lungs. As adoption of EVLP technology becomes more widespread, we may begin to see future implementation of these potential applications into the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.
ORCID-Profile: Alice L Zhou, Emily L Larson, Jessica M Ruck, Errol L Bush
Zitieren
APA
Zhou, A. L., Larson, E. L., Ruck, J. M., Ha, J. S., Casillan, A. J., & Bush, E. L. (2023). Current status and future potential of ex vivo lung perfusion in clinical lung transplantation. Artificial Organs, 47(11), 1700-1709. https://doi.org/10.1111/aor.14607
Vancouver
Zhou AL, Larson EL, Ruck JM, Ha JS, Casillan AJ, Bush EL. Current status and future potential of ex vivo lung perfusion in clinical lung transplantation. Artificial Organs. 2023;47(11):1700-1709. doi:10.1111/aor.14607
BibTeX
@article{Zhou2023,
author = {Zhou, Alice L and Larson, Emily L and Ruck, Jessica M and Ha, Jinny S and Casillan, Alfred J and Bush, Errol L},
title = {Current status and future potential of ex vivo lung perfusion in clinical lung transplantation},
journal = {Artificial Organs},
year = {2023},
volume = {47},
number = {11},
pages = {1700--1709},
doi = {10.1111/aor.14607}
}
EUVIMED